Ulcerative colitis: Combination study with guselkumab and golimumab (DUET-UC)

ClinicalTrials.gov ID: NCT05242484
Sponsor: Janssen Research & Development, LLC

Official title:
A Phase 2b Randomized, Double-Blind, Active and Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy and Safety of Guselkumab and Golimumab Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis.

Study overview:
Study to Evaluate the Efficacy and Safety of JNJ-78934804 Compared to Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colitis Who Have Had an Inadequate Response, Loss of Response, or Intolerance to at Least One Approved Advanced Therapy.